Search results for "carrier"

showing 10 items of 1256 documents

Mesoporous Silica-Based Materials with Bactericidal Properties

2019

[EN] Bacterial infections are the main cause of chronic infections and even mortality. In fact, due to extensive use of antibiotics and, then, emergence of antibiotic resistance, treatment of such infections by conventional antibiotics has become a major concern worldwide. One of the promising strategies to treat infection diseases is the use of nanomaterials. Among them, mesoporous silica materials (MSMs) have attracted burgeoning attention due to high surface area, tunable pore/particle size, and easy surface functionalization. This review discusses how one can exploit capacities of MSMs to design and fabricate multifunctional/controllable drug delivery systems (DDSs) to combat bacterial …

medicine.drug_classAntibioticsNanotechnologyBiocompatible Materials02 engineering and technologyMicrobial Sensitivity Tests010402 general chemistryBacterial Physiological Phenomena01 natural sciencesantibioticsBiomaterialsAntibiotic resistanceDrug Delivery SystemsQUIMICA ORGANICAAntibioticsQUIMICA ANALITICAmedicineHigh surface areaHumansGeneral Materials ScienceControllable drug delivery systemsSettore CHIM/02 - Chimica FisicaDrug Carrierscontrollable drug delivery systemsBacteriaChemistryQUIMICA INORGANICABiofilmGeneral ChemistryMesoporous silica021001 nanoscience & nanotechnologyAntimicrobialSilicon Dioxide0104 chemical sciencesAnti-Bacterial AgentsNanostructuresmesoporous silica materialsBiofilmsDrug deliveryMesoporous silica materialsSurface modificationNanoparticlesnanoparticles0210 nano-technologyPorosityBiotechnology
researchProduct

Identification and characterization of a monoclonal antibody to the membrane fatty acid binding protein

1992

A monoclonal antibody to the rat liver membrane fatty acid binding protein (MFABP) was prepared by immunizing mice with purified MFABP isolated from solubilized rat liver plasma membrane proteins by oleate-agarose affinity chromatography technique. The monoclonal antibody K15/6 identified a single 40 kDa protein in rat liver plasma membranes with pI values of 8.5, 8.8 and 9.0, which is identical to the authentic MFABP, but clearly distinct from rat mitochondrial GOT. The antibody K15/6 selectively inhibited cellular influx as well as membrane binding of fatty acids, but not of cholesterol or vitamin E. The same antibody was used in immunofluorescence, ELISA and Western blot analysis to dete…

medicine.drug_classBlotting WesternImmunoblottingBiophysicsFluorescent Antibody TechniqueEnzyme-Linked Immunosorbent AssayNerve Tissue ProteinsFatty Acid-Binding ProteinsMonoclonal antibodyBiochemistryFatty acid-binding proteinCell LineMiceEndocrinologyAffinity chromatographymedicineAnimalsHumanschemistry.chemical_classificationMice Inbred BALB CbiologyMembrane transport proteinTumor Suppressor ProteinsBinding proteinCell MembraneFatty AcidsAntibodies MonoclonalFatty acidMolecular biologyNeoplasm ProteinsRatsLiverchemistryMembrane proteinBiochemistrybiology.proteinElectrophoresis Polyacrylamide GelAntibodyCarrier ProteinsFatty Acid-Binding Protein 7Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism
researchProduct

The role of the Thomsen-Friedenreich antigen as a tumor-associated molecule.

1990

The Thomsen-Friedenreich antigen (Gal-GalNAc) represents a tumor-associated molecule, which is assumed to be one of the few chemically well-defined antigens with a proven association with malignancy. In order to analyze the role of the carbohydrate structure Gal-GalNAc for gastrointestinal tumors, we immunized Balb/c mice with MCF-7 breast tumor cells together with synthetic Gal-GalNAc linked to a BSA carrier. One monoclonal antibody (82-A6) was established which recognizes the Thomsen-Friedenreich antigen according to the biochemical and serological analysis presented here. In contrast to the studies performed in the past, immunohistochemical results using this antibody 82-A6 did not exhib…

medicine.drug_classHealth Toxicology and MutagenesisDisaccharidesMonoclonal antibodyMalignancyAntibodiesEpitopeAntigenAntibody SpecificityAntigens NeoplasmTumor Cells CulturedmedicineHumansAntigens Tumor-Associated Carbohydratechemistry.chemical_classificationMolecular StructurebiologyThomsen-Friedenreich AntigenPublic Health Environmental and Occupational Healthmedicine.diseaseMolecular biologyMolecular Weightcarbohydrates (lipids)chemistrybiology.proteinImmunohistochemistryAntibodyCarrier ProteinsGlycoproteinResearch ArticleEnvironmental Health Perspectives
researchProduct

Clinical Trial Results of Peginterferons in Combination with Ribavirin

2003

Of the large number of patients chronically infected with hepatitis C virus (HCV), only about one third have progressive liver disease, and will eventually develop cirrhosis and hepatocellular carcinoma. These are the patients for whom effective antiviral treatment is most needed. Therapy is currently recommended for patients with chronic hepatitis C who have abnormal alanine aminotransferase (ALT) levels, detectable hepatitis C virus ribonucleic acid (HCV RNA) in the blood, and significant necroinflammatory changes and/or fibrosis on liver biopsy. The current gold standard in terms of treatment efficacy is the combination of peginterferon (PEG-IFN) and ribavirin. The overall sustained viro…

medicine.medical_specialtyCirrhosisHepatitis C virusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyDrug Administration SchedulePolyethylene Glycolsantiviral agentchemistry.chemical_compoundPharmacotherapyInternal medicineRibavirinmedicineHumansClinical Trials as TopicDrug CarriersHepatologymedicine.diagnostic_testbusiness.industryRibavirinInterferon-alphavirus diseasesHepatitis CHepatitis C Chronicmedicine.diseaseRecombinant Proteinsdigestive system diseasesTreatment OutcomechemistryLiver biopsyHepatocellular carcinomaImmunologyclinical trials hepatitis CDrug Therapy CombinationbusinessViral loadSeminars in Liver Disease
researchProduct

ATG16L1 contribution to Crohnʼs disease risk in Sicily

2011

medicine.medical_specialtyCrohn's diseaseSettore MED/09 - Medicina InternaPolymorphism Geneticbusiness.industryGastroenterologyAutophagy-Related Proteinsmedicine.diseaseGastroenterologyCrohn DiseaseRisk FactorsInternal medicinemedicineHumansImmunology and AllergyCarrier ProteinsbusinessCrohn's disease.genetics.ATG16L1SicilyATG16L1Inflammatory Bowel Diseases
researchProduct

Identification of a novel mutation of MTP gene in a patient with abetalipoproteinemia.

2011

Abetalipoproteinemia (ABL), or Bassen-Kornzweig syndrome, is a rare autosomal recessive disorder of lipoprotein metabolism, characterized by fat malabsorption, hypocholesterolemia retinitis pigmentosa, progressive neuropathy and acanthocytosis from early infancy. We describe the clinical and molecular characterization of a 6-month-old infant born of consanguineous, apparently healthy parents from Iran. The patient was hospitalized because of failure to thrive, greasy stool and vomiting. The patient's serum lipid profile, the clinical phenotype and the duodenal histology suggested the clinical diagnosis of ABL. The MTP gene analysis by direct sequencing revealed a novel homozygous mutation (…

medicine.medical_specialtyHeterozygoteSettore MED/09 - Medicina InternaDuodenumSpecialties of internal medicineInternal medicineRetinitis pigmentosamedicineHumansgeneticsFamily HealthMTP gene mutations.ABLHepatologymedicine.diagnostic_testApoB-containing lipoproteins.business.industryAbetalipoproteinemiaInfantAbetalipoproteinemia.Heterozygote advantageGeneral Medicinemedicine.diseaseLipidsAbetalipoproteinemiaFat malabsorptionHypocholesterolemiaEndocrinologyPhenotypeRC581-951Failure to thriveFemaleHypocholesterolemia.medicine.symptomLipid profilebusinessCarrier Proteins
researchProduct

Hormonal and nutritional control of L‐carnitine uptake in myoblastic C2C12 cells

2008

L-Carnitine plays an important role in skeletal muscle bioenergetics, and its bioavailability and thus its import may be crucial for muscle function. We studied the effect of thyroid hormone, insulin, and iron overload, hormones and nutrients known to alter muscle metabolism, on L-carnitine import into C2C12 cells. We report here L-carnitine uptake is increased by thyroid hormones and decreased by iron. Insulin was found to be ineffective in altering the L-carnitine uptake.

medicine.medical_specialtyIron OverloadOrganic Cation Transport ProteinsBioenergeticsPhysiologymedicine.medical_treatmentBiologyCell LineCellular and Molecular NeuroscienceCarnitinePhysiology (medical)Internal medicinemedicineHumansInsulinNutritional Physiological PhenomenaRNA MessengerCarnitineMuscle SkeletalSolute Carrier Family 22 Member 5InsulinThyroidSkeletal muscleMetabolismBlotting NorthernHormonesmedicine.anatomical_structureEndocrinologyTriiodothyronineNeurology (clinical)Iron CompoundsEndocrine glandHormonemedicine.drugMuscle & Nerve
researchProduct

The dilemma for patients with chronic hepatitis C: treat now or warehouse?

2013

Dual therapy with peginterferon and ribavirin, the only treatent for chronic hepatitis C available In Italy and in many other ountries worldwide up to 2013, obtains satisfactory response ates in infections with hepatitis C virus (HCV) genotype 2, but far rom optimal for other genotypes [1,2]. Eradication requires 6–12 onths of therapy, with significant inconvenience for patients: dverse reactions force premature termination in about 20% of atients and reduced the quality of life for almost all who persist n treatment. In view of the important and prolonged side effects, nterferon-based treatment is perceived as a nightmare by many symptomatic,well-being, socially activepatients (the largema…

medicine.medical_specialtyPediatricsTime FactorsProlineHepatitis C virusAlpha interferonmedicine.disease_causeAntiviral AgentsTelaprevirPolyethylene Glycolschemistry.chemical_compoundLiver diseaseBoceprevirDrug DiscoveryRibavirinmedicineHumansProtease InhibitorsAdverse effectWatchful WaitingDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaHepatitis C Chronicmedicine.diseaseSurgeryEastern europeanchemistryHCVDrug Therapy CombinationbusinessOligopeptidesmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Confronting the psychological burden of haemophilia

2010

Providing comprehensive care, counselling and support to haemophilic patients, and their parents have always been quite complex for haemophilia treatment centres. Nowadays, starting with recent developments in genetic counselling, prenatal diagnosis and carrier testing, the psychological burden on patients and parents might possibly have increased, compared with even the recent past. The emotional strains and worries associated with a possibly affected newborn and his care through childhood and adolescence may also have a grievous impact on couple dynamics and marital relationship. The impact may be even higher in families in which haemophilia is newly diagnosed. The main psychological prob…

medicine.medical_specialtyPregnancybusiness.industryGenetic counselingMEDLINEPrenatal diagnosisHematologyGeneral MedicineCarrier testingHaemophiliamedicine.diseasehemic and lymphatic diseasesmedicinePsychological supportPsychiatrybusinessPsychosocialGenetics (clinical)Haemophilia
researchProduct

Model-specific effects of bumetanide on epileptiform activity in the in-vitro intact hippocampus of the newborn mouse.

2007

The immature brain has a higher susceptibility to develop seizures, which often respond poorly to classical pharmacological treatment. It has been recently suggested that bumetanide, which blocks Na(+)-dependent K(+)-Cl(-)-cotransporter isoform 1 (NKCC1) and thus attenuates depolarizing GABAergic responses, could soothe epileptiform activity in immature nervous systems. To evaluate whether bumetanide consistently attenuates epileptiform activity, we investigated the effect of 10 microM bumetanide in five different in-vitro epilepsy models using field potential recordings in the CA3 region of intact mouse hippocampal preparations at postnatal day 4-7. Bumetanide reduced amplitude and frequen…

medicine.medical_specialtySodium-Potassium-Chloride SymportersHippocampusKainate receptorHippocampal formationIn Vitro TechniquesHippocampusMembrane PotentialsCellular and Molecular Neurosciencechemistry.chemical_compoundEpilepsyMiceChloride ChannelsInternal medicinemedicineAnimalsSolute Carrier Family 12 Member 2MagnesiumBumetanidePharmacologyEpilepsyDepolarizationStrychninemedicine.diseaseDisease Models AnimalEndocrinologychemistryAnimals NewbornGabazinePotassiumBumetanidemedicine.drugNeuropharmacology
researchProduct